Abstract accepted for poster presentation at the ESMO Immuno-Oncology Congress 2022, Geneva, Switzerland 7-9 December 2022.

On November 1, 2022 Hubro Therapeutics reported that our abstract has been accepted for poster presentation (display) at the ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress 2022, Geneva, Switzerland 7-9 December 2022 (Press release, Hubro Therapeutics, NOV 1, 2022, View Source [SID1234622701]). The presentation is supported by the presence of Company employees and the Principal Investigator for the trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Abstract # 514; A Phase I Study of the cancer-specific vaccine FMPV-1 in Healthy Male Subjects to Assess Safety and Immune Response

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!